

CREATING TOMORROW'S SOLUTIONS

ESETEC[®]

FOLDTEC®

LIBATEC

PLASMITEC®

BIOPHARMACEUTICALS I CONTRACT MANUFACTURING

WACKER BIOTECH – ENGAGE THE EXPERTS IN ADVANCED THERAPIES

Your Needs Are Driving Our Innovation!

WACKER's corporate R&D in Munich with > 200 researchers and close collaboration with universities and research institutions continuously develops new production platforms and technologies for all types of biopharmaceuticals including pDNA, mRNA and LNP. Competitive, outstanding solutions are our trademarks.

CUTTING-EDGE TECHNOLOGIES

Wacker Biotech offers efficient and cost-saving technologies for production of biologics.



E. coli Controlled Secretion Technology

Allowing for high yields of correctly folded proteins secreted in the fermentation broth.



E. coli Refolding Technology

Unique solutions for the sophisticated manufacturing of biopharmaceuticals by refolding.



Platform for GMP Production of Live Biotherapeutic Products

Suitable for a wide range of LBPs and fermentation regimes including anaerobic cultivation.

VACCINES

Extensive GMP Manufacturing

of Vaccines incl. mRNA Expertise in process development and manufacturing of a variety of vaccine products.

mRNA

mRNA Manufacturing mRNA production incl. LNP formulation under one roof.

PLASMITEC®

Plasmid DNA Manufacturing

Versatile plug-and-play platform for manufacturing of pDNA for advanced therapies.

PASylation®

Extending the Plasma Half-Life of Biopharmaceuticals Collaboration with XL-protein GmbH to produce high violate of DASylated

produce high yields of PASylated biologics.

PEGylation

Extending the Plasma Half-Life of Biopharmaceuticals

Expertise in developing and performing the PEGylation step.



Learn more about our technologies: www.wacker.com/biologics

ESETEC[®], FOLDTEC[®], LIBATEC[®] and PLASMITEC[®] are registered trademarks of Wacker Chemie AG.

100 YEARS OF RELIABILITY, 20 YEARS OF EXPERIENCE IN BIOLOGICS, OVER 200 PROJECTS, 4 COMMERCIAL PRODUCTS AND SATISFIED CLIENTS.

Here is what they say about us:

- "We are very pleased with the high technical competence, reliability and support of the WACKER team to bring our lead candidate into the clinic as planned – WACKER is a true partner in this project." Juha Yrjänheikki, CEO Aurealis Therapeutics
- "A partnership with WACKER, one of the world's leading microbial drug CDMOs, provides a significant boost to Helixmith. Having a strong partner like WACKER provides us with additional confidence as we pursue our global blockbuster pipeline." Seungshin Yu, CEO Helixmith
- "In WACKER we have found a highly competent partner for ensuring that we have a secure supply of raw materials for our industrial scale production." Dr. Wolfram Strobl, General Manager Fresenius Medical Care
- "This approval represents a significant milestone in Chiesi's work to bring Retavase[®] back to the US market. WACKER is a proven leader in microbial technology. The collaborative effort and partnership have been outstanding." Alan Roberts, Senior Vice President, Scientific Affairs at Chiesi
- "We selected WACKER among competing CMOs because their proprietary bacterial expression technology provides a significant yield of fully refolded PAS-nomacopan, and we believe working with WACKER provides the best path to GMP manufacturing of long-acting PAS-nomacopan for use in GA clinical trials. WACKER has proven to be an exceptional contract manufacturing partner for the parent drug nomacopan, and we look forward to our continued relationship with them." Dr. Miles Nunn, Chief Scientific Officer at Akari

Customer Proximity From Research to Delivery Wacker Biotech expertly delivers on a broad range of service offerings, ready to fulfill your demand for clinical and commercial supply.

Products

- Recombinant proteins
- Vaccines
- Live Biotherapeutic Products
- Plasmid DNA
- mRNA incl. LNP formulation

Services

Process Development and Transfer

- Strain development
- Process development
- Process transfer
- Analytical development

GMP Manufacturing

- Cell banking
- Drug substance
- Drug product
- Conjugation (PEGylation/PASylation[®]



GLOBALLY OPERATING GMP FACILITIES FOR ADVANCED THERAPIES

pDNA

San Diego, USA

- 43 L stirred single use bioreactor
- 650 L stainless steel stirred fermenter
- pDNA process development
- QC/QA for pDNA on site
- Cell banking
- CA FDA licensed



mRN/

- Halle (Saale), Germany
- mRNA competence center
- Production of pDNA and mRNA incl. LNP formulation
- 4 production lines (Class C)
- 2 x 30 L, 2 x 3 L IVT scale
- g to kg scale within a few months
- Flexibility based on fast-track supply of raw materials
- Facility for pandamic preparedness



Halle (Saale), Germany

Amsterdam, the Netherlands

- Production of pDNA and mRNA incl. LNP formulation
- 350 L stainless steel stirred tank fermenter
- Flexible to accommodate customized mRNA processes
- Center of Excellence in process development of mRNA-based processes



Amsterdam, the Netherlands

GMP FACILITIES FOR PROTEINS, LIVE BIOTHERAPEUTIC PRODUCTS & VACCINES

Proteins

Jena, Germany

- 350 L stainless steel stirred tank fermenter
- Recombinant protein manufacturing
- Strong process development
- Cell banking
- Commercial and clinical supply
- EMA and FDA approved



Halle (Saale), Germany

- **1,500 L** stainless steel stirred tank fermenter
- Recombinant protein manufacturing
- Strong process development
- mRNA Center of Excellence
- Commercial and clinical supply
- EMA and FDA approved



Proteins, Live Biotherapeutic Products and Vaccines

Amsterdam, the Netherlands

- 250 L stirred single use bioreactor
- **1,500 L** stainless steel stirred tank fermenter
- Live bacteria, proteins, vaccines incl. mRNA
- Cell banking
- Fill & finish
- Commercial and clinical supply
- Biosafety Level 2 certified
- EMA and FDA approved







Take a virtual 360° tour through our production sites: https://biologics-plant-tour.wacker.com



Wacker Biotech GmbH Jena and Halle, Germany Phone: + 49 3641 5348-0

Wacker Biotech B.V. Amsterdam, the Netherlands Phone: +31 20 750 3600

Wacker Biotech US Inc. San Diego, CA/USA Phone: +1 858-875-4700 info.biologics@wacker.com www.wacker.com/biologics

Follow us on: X 🕞 in



The data presented in this medium are in accordance with the present state of our knowledge but do not absolve the user from carefully checking all supplies immediately on receipt. We reserve the right to alter product constants within the scope of technical progress or new developments. The recommendations made in this medium should be checked by preliminary trials because of conditions during processing over which we have no control, especially where other companies' raw materials are also being used. The information provided by us does not absolve the user from the obligation of investigating the possibility of infringement of third parties' rights and, if necessary, clarifying the position. Recommendations for use do not constitute a warranty, either express or implied, of the fitness or suitability of the product for a particular purpose.